Belch J J, McArdle B, Madhok R, McLaughlin K, Capell H A, Forbes C D, Sturrock R D
Ann Rheum Dis. 1984 Dec;43(6):774-7. doi: 10.1136/ard.43.6.774.
We have investigated the fibrinolytic status of 56 patients with rheumatoid arthritis (RA). Plasma fibrinogen and plasminogen were significantly elevated. Levels of these two substrates, along with alpha 2 macroglobulin and antithrombin III correlated with disease activity. Plasminogen activator (PA) activity was decreased in patients with severe disease. Twelve patients were given stanozolol, a fibrinolytic enhancing agent, for two months as a test for endothelial production of plasminogen activator. This caused a significant increase in blood plasminogen and PA activity. Five patients received a two-week course of stanozolol with joint aspiration before and after. Joint plasminogen levels were increased. We suggest that inadequate fibrinolysis occurs in RA, and that this may contribute to some of the pathological features of the disease. It is possible to stimulate both blood and joint fibrinolysis by stanozolol. A more prolonged increase in plasminogen activator activity might decrease joint fibrin deposition, and stanozolol should be investigated as a therapeutic agent in RA.
我们研究了56例类风湿关节炎（RA）患者的纤溶状态。血浆纤维蛋白原和纤溶酶原显著升高。这两种底物的水平，以及α2巨球蛋白和抗凝血酶III与疾病活动相关。重症患者的纤溶酶原激活物（PA）活性降低。12例患者接受了两个月的司坦唑醇治疗，司坦唑醇是一种纤溶增强剂，以此检测内皮细胞纤溶酶原激活物的产生。这导致血液纤溶酶原和PA活性显著增加。5例患者在前后关节穿刺的同时接受了为期两周的司坦唑醇治疗。关节纤溶酶原水平升高。我们认为RA中存在纤溶不足，这可能导致了该疾病的一些病理特征。司坦唑醇可以刺激血液和关节的纤溶。纤溶酶原激活物活性的更持久增加可能会减少关节纤维蛋白沉积，司坦唑醇应作为RA的治疗药物进行研究。
